Results 151 to 160 of about 1,763 (188)
After a variable period of activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment, patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations develop resistance to these TKIs. In some cases,
Domenico Galetta, Antonio Rossi
exaly +2 more sources
Management of Oligoprogression in Patients With Metastatic NSCLC Harboring ALK Rearrangements [PDF]
Personalized treatment based on driver molecular alterations, such as ALK rearrangement, has revolutionized the therapeutic management of advanced oncogene-addicted NSCLC patients.
Silvia Novello +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer
Seminars in Radiation Oncology, 2021Oligometastatic disease was originally defined by Hellman and Weichselbaum as an intermediate-state existing between locally confined and widely disseminated malignancy, whose natural history could be positively impacted with systemic and importantly local therapies such as radiation.
Matthew P, Deek +2 more
openaire +2 more sources
Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease
The Cancer Journal, 2020Abstract Historical theories of metastasis have been informed by the seed and soil hypothesis, the Halsteadian paradigm proposing an orderly spread from local to distant sites, and the presumption that cancer is an inherently systemic process even in the earliest cases.
Corey C, Foster +2 more
openaire +2 more sources
Background: The evidence base for the management of oligoprogression in metastatic melanoma (MM) is limited. To our knowledge, this study presents the first analysis of the local benefit (LB) of radiotherapy combined with hyperthermia during systemic ...
Mateusz Spałek +2 more
exaly +2 more sources
The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Oligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease.
D Palma, F McDonald, A C Tree
exaly +2 more sources
SBRT for oligoprogressive oncogene addicted NSCLC
Lung Cancer, 2017Lung cancer is one of the leading causes of cancer death in men and women and treatment outcome continues to lag behind other common cancer types. A subset of lung adenocarcinoma patients exhibit a somatic mutation in EGFR or an ALK rearrangement. In these patients, targeted TKI therapy results in higher response rates, improved PFS and reduced side ...
Basler, L +2 more
openaire +4 more sources
Local control strategies for management of NSCLC with oligoprogressive disease
Cancer Treatment Reviews, 2023Progresses of systemic treatments in advanced non-small cell lung cancer (NSCLC), such as immune checkpoint blockers (ICB) and targeted therapies, led to the increased incidence of oligoprogressive disease (OPD). The OPD is a subtype of oligometastatic disease (OMD) defined as a progression of a limited number of lesions during systemic treatment ...
Mavrikios, Antoine +12 more
openaire +2 more sources
Oligometastatic and oligoprogressive extracranial disease
2023Abstract With the advent of modern imaging and frequent surveillance, some patients are shown to have progressive metastatic disease with or without symptoms. Some of these patients with limited sites of metastatic disease are often classified as oligometastatic, though a strict definition does not exist.
openaire +1 more source
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials
International Journal of Radiation Oncology*Biology*Physics, 2022The successes of local therapy for oligometastatic cancers cannot be extrapolated to oligoprogressive disease (OPD) because they are distinct clinical entities. Given the limited prospective data on OPD to date, summative analyses are urgently needed.Inclusion criteria for this Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-
Hans, Kim +6 more
openaire +2 more sources

